Y225 (emicizumab biosimilar)
/ YZY Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 24, 2025
Wuhan YZY Biopharma has received Investigational New Drug approval from China’s National Medical Products Administration for Y225, its biosimilar to Roche’s Hemlibra (emicizumab injection), a bispecific antibody used in the prophylactic treatment of hemophilia A.
(TipRanks)
New trial • Hemophilia A
1 to 1
Of
1
Go to page
1